Protocol to Obtain Blood for Discovery of Novel Biomarkers and Potential Therapeutic Targets in Chronic Lymphocytic Leukemia
| Status: | Withdrawn |
|---|---|
| Conditions: | Blood Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/17/2018 |
| Start Date: | May 2010 |
| End Date: | February 2011 |
The purpose of this study is to collect a blood sample from patients with Chronic Lymphocytic
Leukemia (CLL) and from volunteers without CLL.
Leukemia (CLL) and from volunteers without CLL.
The blood sample will be used in the laboratory to perform focused studies on Chronic
Lymphocytic Leukemia (CLL).
Lymphocytic Leukemia (CLL).
Inclusion Criteria:
- Patients undergoing routine blood draws as part of their ongoing follow-up care for
CLL at the Norris Cotton Cancer Center of DHMC.
- Normal donors who have no history of active or prior hematologic malignancy.
Exclusion Criteria:
- Patients who have received cytotoxic drug, oral or intravenous steroid or targeted
antibody therapy for their CLL, other hematologic malignancy or other disease process
within the past 2 months are excluded. Use of intravenous immunoglobulin (IVIg) is not
a reason for exclusion.
- Normal donors who have a history of steroid use, immunosuppression therapy or
autoimmune disease are excluded.
We found this trial at
1
site
Dartmouth Hitchcock Medical Center Dartmouth-Hitchcock is a national leader in patient-centered health care and building...
Click here to add this to my saved trials
